undamentalytics Newsletter
Sign in

Actinium Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Actinium Pharmaceuticals, Inc. had total assets of $51.8m, total liabilities of $43.9m and shareholders' equity of $7.8m. It held $48.0m in cash against $0 of debt.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2010Dec 20102011Dec 20112021Dec 20212022Dec 20222023Dec 20232025Dec 2025
Cash and equivalents06781097748
Receivables—0————
Inventory—0————
Total current assets06801117849
Total assets06801148152
Accounts payable00————
Deferred revenue (current)——1———
Total current liabilities0571188
Total debt0061080
Total liabilities007484544
Shareholders' equity017466368
Non-controlling interests and other (assets − liabilities − equity)−05————
Shares outstanding11m—22m26m28m31m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ATNM vs STTKATNM vs MNOVATNM vs LGVN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Actinium Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Actinium Pharmaceuticals, Inc.